Patents Assigned to Samsung Life Public Welfare Foundation
  • Publication number: 20200355615
    Abstract: The present invention relates to a target gene-detecting device and a method for detecting a target gene. According to an aspect, a target gene-detecting device can be conveniently fabricated at low cost by employing a porous substrate or a method for detecting a target gene allows the pretreatment of a sample, the extraction of a nucleic acid, the amplification of a nucleic acid, and the detection of a target gene to be conducted at high accuracy and specificity in an integral system, with no contamination plausibility and can be thus useful for gene inspection.
    Type: Application
    Filed: August 28, 2018
    Publication date: November 12, 2020
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Min Young LEE, Min Hee KANG, Hyun Ju PARK, Dong Ho KIM, Sung Gyu PARK, Ho Sang JUNG
  • Patent number: 10815533
    Abstract: The present invention relates to a biomarker composition for diagnosing anticancer drug resistance of gastric cancer, including an FGFR2-ACSL5 fusion gene or a protein that the fusion gene encodes, a composition and a kit for diagnosing anticancer drug resistance of gastric cancer, including a preparation which detects an mRNA or protein of the fusion gene, and a method for diagnosing anticancer drug resistance of gastric cancer by using the biomarker. It is possible to diagnose in advance whether resistance to the drug will be exhibited during the treatment with the FGFR inhibitor by detecting an mRNA of the FGFR2-ACSL5 fusion gene according to the present invention or a protein which the gene encodes in a tissue derived from the patient with gastric cancer, so that the treatment efficiency can be enhanced by applying a more appropriate treatment to the patient.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: October 27, 2020
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Jeeyun Lee, Kyoung Mee Kim
  • Patent number: 10765720
    Abstract: A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 8, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park, So Yoon Ahn, Dong Kyung Sung, Young Eun Kim, Jae Ho Kim
  • Publication number: 20200269056
    Abstract: Provided are a method for supplying power to an implantable medical device and a power supply system for an implantable medical device. The power supply system supplies a constant power to the implantable medical device even when there is a movement in a body, by using a wireless power transmitter unit, a wireless power receiver unit, and a piezoelectric sensor unit stacked at the wireless power receiver unit.
    Type: Application
    Filed: June 15, 2016
    Publication date: August 27, 2020
    Applicants: SAMSUNG ELECTRONICS CO., LTD., SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Manseung HEO, Jinho OH, Eunkyoung PARK, Minyoung LEE, Kyusung LEE
  • Publication number: 20200239474
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 30, 2020
    Applicants: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hwan Geun CHOI, Jong Bae PARK, Eunhwa KO, Jung Beom SON, Joong-heui CHO, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Nam Doo KIM, Yunho LEE, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Jae Hyun BAE, Eunmi HONG, Tae-ho JANG, Sang Bum KIM, Seung Hoon LEE, Do-Hyun NAM
  • Patent number: 10723997
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: July 28, 2020
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park, Dong Kyung Sung, So Yoon Ahn
  • Publication number: 20200178913
    Abstract: Provided is a radiation shielding device according to various embodiments. The radiation shielding device includes: a body structure forming a receiving space receiving a user's body part, wherein a through passage penetrating an inside of the body structure is formed in the body structure; a shielding unit positioned to reciprocatively move along the through passage, wherein a shielding pad configured to shield the radiation is included in a portion of the shielding unit; and a driver configured to transfer a driving force to the shielding unit to cause the shielding unit to reciprocatively move.
    Type: Application
    Filed: October 12, 2017
    Publication date: June 11, 2020
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Sang Hun Kim, Sung Ryong Kim, Pyoung Jeon, Won Hong Cho
  • Patent number: 10669526
    Abstract: The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 2, 2020
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Chul Won Ha, Jin A. Kim
  • Patent number: 10669340
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof against EGFRvIII (Epidermal Growth Factor Receptor Variant III), a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a composition for preventing or treating cancer, which comprises the same, a composition for diagnosing cancer, which comprises the same, and a kit for diagnosing cancer, which comprise the composition for diagnosing cancer.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: June 2, 2020
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Do-Hyun Nam, Hyunkyu Park
  • Publication number: 20200146659
    Abstract: Provided is a tongue separation device including: a body unit including a contact surface fixing a tongue; a support unit arranged at one end portion of the body unit and supporting the body unit from outside a mouth; a tooth mounting unit arranged at one surface of the support unit adjacent to a first region of the body unit, mounting the teeth in a state where the body unit is inserted into the mouth, and including an upper surface mounting upper teeth among the teeth and a lower surface mounting lower teeth among the teeth; and a tongue position checking unit including an opening formed at the support unit to check a position of the tongue from outside the mouth, wherein a first portion of the contact surface of the body unit adjacent to the one end portion of the body unit is arranged over a virtual extension surface that passes through a center of the support unit and crosses between the upper surface and the lower surface of the tooth mounting unit, and a second portion of the contact surface of the bod
    Type: Application
    Filed: March 28, 2018
    Publication date: May 14, 2020
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Sang Gyu Ju, Chae-Seon Hong
  • Patent number: 10640777
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 5, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10604571
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10604572
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Publication number: 20200093414
    Abstract: The purpose of the present invention is to diagnose a neurological disease such as dementia by using virtual reality, and the present invention receives a neurological disease-diagnosing problem from an external device, displays a virtual reality image through a display on the basis of the received neurological disease-diagnosing problem, and performs an examination using the virtual reality image according to user actions detected through various sensors. This process can be performed when linked with an external device such as a PC or a smart phone. Particularly, with respect to the neurological disease-diagnosing problem, the present invention includes: a first screen for introducing at least one object in a virtual reality space and hiding the same; and a second screen haying a question on the hidden object. According to the present invention, neurological disease such as dementia can be conveniently examined without inconveniencing or burdening a patient.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 26, 2020
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Duk Lyul NA, Ko Woon KIM, Ju Hee CHIN, Byung Hwa LEE, Jong Doo CHOI, Jee Hyun CHOI, Hio Been HAN
  • Patent number: 10569102
    Abstract: A system for inducing respiration according to one embodiment of the present invention comprises: an imaging unit for picking a respiration image of a patient; a respiration signal conversion unit for obtaining a respiration signal of the patient by image processing, and tracking and analyzing the respiration image of the patient obtained from the imaging unit; and a respiration determination unit for determining one or more of whether the obtained respiration signal is suitable for radiation treatment, whether the obtained respiration signal is stable, and whether a matching score between the respiration signal of the patient and a guide respiration is greater than a predetermined reference value; and a respiration guide unit for providing the respiration signal of the patient, obtained from the respiration signal conversion unit, together with a stored guide signal.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 25, 2020
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Youngyih Han, Hee Chul Park, Eun Hyuk Shin, Jung Suk Shin, Jin Sung Kim
  • Publication number: 20200046380
    Abstract: Provided is a femoral tunnel guide device including: a handle; a guide tube coupled to the handle and extending in one direction: and an offset unit extending from the guide tube and spaced apart by a predetermined distance from a virtual extension line of the guide tube in the one direction.
    Type: Application
    Filed: September 27, 2017
    Publication date: February 13, 2020
    Applicant: Samsung Life Public Welfare Foundation
    Inventor: Chul Won Ha
  • Publication number: 20200049638
    Abstract: Provided are a method and a device capable of: generating a first alternating current magnetic field passing through a chamber having a cell disposed therein, by using a plurality of primary coils arranged on a first plane; receiving a second alternating current magnetic field by using a plurality of secondary coils arranged on a second plane; and measuring an impedance change of a cell by using the first alternating current magnetic field and the second alternating current magnetic field.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 13, 2020
    Applicants: Samsung Electronics Co., Ltd., Samsung Life Public Welfare Foundation
    Inventors: Manseung HEO, Eunhyuk CHANG, Duk L NA, Kyusung LEE
  • Patent number: 10548507
    Abstract: A biological brain age is calculated by measuring a brain cortex thickness of each region in a brain MRI image of a person to be examined, and comparing the measured brain cortex thickness with normal control group information. A device for calculating the biological brain includes an image information input unit to input an MRI brain image of a person to be examined, a brain age calculation control unit to control a biological brain age calculation operation of the person to be examined based on the MRI brain image, a brain thickness measuring unit to measure a brain cortex thickness of each region in the MRI brain image, and a brain age calculating unit to match the measured brain cortex thickness with a normal range of brain thickness of each age, and calculate a biological brain age of the person to be examined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: February 4, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Duk L. Na, Sang Won Seo, Jun Kyung Seong, Changsoo Kim
  • Patent number: 10510448
    Abstract: The present invention relates to a method and system for providing ‘diagnosis-aiding information’, the method and system being capable of diagnosing cancer and the like of a patient by using medical imaging.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: December 17, 2019
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Won Jae Lee, Jae Hun Kim
  • Patent number: 10493104
    Abstract: The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: December 3, 2019
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park